Mohamed Fawzy Salman
Cairo, Egypt
NCT Number: NCT07741214
Patients with obstructed flow due to BPH will be enrolled into 2 groups, group will undergo TURP and the other group will undergo Low power HOLEP
Interested in participating?
Request Info50 year and older
Male
Interventional
Not applicable
Cairo, Egypt
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients who will undergo transurethral resection of the prostate
Patients who will undergo transurethral resection of the prostate
Time frame: 6 months
The International Prostate Symptom Score (IPSS) can be utilized to measure the severity of lower urinary tract symptoms.
It is a validated, reproducible scoring system to assess disease severity and response to therapy.
The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.
Al-Azhar University
Other
Low Power HOLEP Versus TURP in Management of BPH
Acronym: HOLEP vs TURP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07209150
Antibiotic Prophylaxis, BPH With Urinary Obstruction
View Trial DetailsNCT05652023
BPH With Urinary Obstruction, Bladder Dysfunction
Rochester, Minnesota, United States
View Trial DetailsNCT07187180
BPH With Symptomatic Lower Urinary Tract Symptoms, BPH With Urinary Obstruction
Cleveland, Ohio, United States
View Trial DetailsNCT06037356
BPH With Urinary Obstruction, Female Urogenital Diseases
Hong Kong, China
View Trial Details